MarketInOut Stock Screener Log In | Sign Up
 

AIM ImmunoTech Inc

NYSE • Healthcare • Biotechnology • Quote as of 09/30/2026 16:00
AIM ImmunoTech Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization7.22 mln
Float30.30 mln
Earnings Date11/17/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2.91
Likely reliable

1-Year Forecast

4.25
Transformational upside

Relative Strength

1 / 100
Severely lagging

Debt / Equity

0.51
Moderate leverage

Pre-Tax Margin

-15,021%
Severely loss-making

Business Description

AIM ImmunoTech Inc. is a US-based medical research company working to develop treatments for cancer, viral infections, and immune system disorders. Its two main products are Ampligen, used to treat chronic fatigue syndrome, and Alferon N Injection, which targets genital warts. The company is also exploring Ampligen as a potential therapy for a wide range of cancers and conditions including HIV, Hepatitis B, and COVID-19. Founded in 1966 and based in Ocala, Florida, the company operated under the name Hemispherx Biopharma Inc. before rebranding in 2019.

Key Fundamentals

EPS-0.69
ROE-2,382
RPS0.01
ROIC-184
ROA-194
Interest Cover-9.72
EBITDA, mln-12.52
EV / EBITDA-0.15
EV / EBIT-0.14
Revenue, mln0.09
EV / Revenue19.19

Quote Details

Last 0.175
Change 0.0015 (0.86%)
Open 0.1772
Volume 982,440
Turnover 171,927
Average Volume 5,966,766

Financial Ratios

Pre-Tax Profit Margin-15,021
Leverage Ratio1.64
Current Ratio2.11
Price / Book0.97
Price / Tangible Book1.24
Debt / Equity0.51
Price / Sales9.94
PEG Ratio0.71

Financial Strength

Altman Z-Score-51.15
Piotroski F-Score 3 / 9
Beneish M-Score-2.91
1-Year Target Price4.25
Short Ratio0.24
Short % of Float7.08

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -16.67% 1 / 100   
1 Month -22.57% 3 / 100   
2 Months -53.21% 1 / 100   
6 Months -70.09% 1 / 100   
1 Year -93.42% 0 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us